パチスロ 山口 市 News

KYORIN Co., Ltd. Announces that its wholly owned subsidiary, パチスロ.(Headquarters :Tokyo, President :Itaru Kojo) launched today パチスロ 山口 市® Tablets 500 as an additional formulation to the パチスロ 山口 市®250 (generic name :mesalazine) already on the market.

Since July 1996, パチスロ. and Nisshin パチスロ. both have marketed パチスロ 山口 市® Tablets 250 and have contributed to the treatment of ulcerative colitis and Crohn's disease.

パチスロ 山口 市® Tablets 500 lessen the burden on patients by reducing the number of tablets currently marketed パチスロ 山口 市® Tablets 250 that are administered per day. パチスロ 山口 市® Tablets 500 were developed for the purpose of improving adherence as well as QOL.

To distinguish them from the round パチスロ 山口 市® Tablets 250, パチスロ 山口 市® Tablets 500 came in a capsule form.

Inflammatory bowel diseases (ulcerative colitis and Crohn's disease) are intractable diseases that hinder social interaction, causing frequent diarrhea and melena. The causes have not been identified and there is no radical treatment. Therefore, the therapeutic goals are suppressing symptoms in the active phase, alleviating the symptoms and keeping the symptoms in a relieved state with the use of mesalazine drugs like パチスロ 山口 市 and steroids.

On October 1, 2008, パチスロ. merged Nisshin パチスロ. into パチスロ. we will exclusively market パチスロ 山口 市® Tablets 250, パチスロ 山口 市® Enema 1g and パチスロ 山口 市® Tablets 500 and will make an ongoing contribution to the treatment of inflammatory bowel diseases by providing the latest information, including peripheral information.